

UC Irvine

ICTS Publications

Title

Insulin-like growth factor in muscle growth and its potential abuse by athletes

Permalink

<https://escholarship.org/uc/item/38k1j42h>

Journal

Western Journal of Medicine, 175(1)

ISSN

00930415

Author

Adams, G. R

Publication Date

2001-07-01

DOI

10.1136/ewjm.175.1.7

License

[CC BY 4.0](#)

Peer reviewed

Insulin-like growth factor in muscle growth and its potential abuse by athletes

Skeletal muscle is an inherently plastic tissue. Evidence suggests that muscles are constantly adapting in both quantity and quality to the changing functional demands imposed by the types and amounts of physical activity routinely performed. To date, the evidence suggests that in adults, activity-induced adaptations of skeletal muscle are orchestrated by local—that is, tissue-level as opposed to systemic—mechanosensitive mechanisms, which appear to include several growth factors and hormones. Of particular recent interest is the growth hormone (GH) and insulin-like growth factor-I (IGF-I) system. In the context of skeletal muscle homeostasis, IGF-I is thought to mediate most of the growth-promoting effects of circulating GH. In addition, it appears to function in a GH-independent autocrine–paracrine mode in this tissue.¹

As information on the mechanisms that modulate

muscle adaptation becomes available in the scientific literature, it is tempting for athletes to apply this knowledge to enhance muscle mass, and hence function, by artificially manipulating these systems. In some cases, this misapplication of information has led to the simplistic notion that exogenous anabolic agents can be used to safely and effectively stimulate or augment muscle. Unfortunately, many of these attempts have been unsuccessful, and in truth, they ignore our understanding of the integrated nature of physiologic systems.

The most obvious problem with misusing anabolic substances is that they are invariably nonspecific. Agents that can stimulate muscle cells to hypertrophy will undoubtedly have effects on other cells and tissues—for example, the effects of GH on prostatic hypertrophy. Another problem is that just as the body is made up of tissues

Gregory R Adams
Department of
physiology and
biophysics
University of California,
Irvine
Irvine, CA 92717-4560
gradams@uci.edu

Competing interests:
None declared

This article was
published in *Br J Sports
Med* 2000;34:412–413.



AP photo/Keystone/tean

Striving to reach peak athletic form, typified by US sprinter Jon Drummond, tempts athletes to misuse anabolic substances

and organs that function as an integrated whole, so muscle comprises different cell types that must also function in unison. For example, a treatment that stimulates muscle cells to hypertrophy must also recruit fibroblasts to strengthen the connective tissues that will transmit the force generated by the muscle cells and must enhance angiogenesis and mitochondrial function. Without this coordination, larger (therefore stronger) muscle cells may develop, but the application of this enhanced contractile function would only damage the structure of the muscle when the unenhanced connective tissue fails.

Results from animal studies are instructive with regard to manipulating IGF-I either directly or through GH. Researchers have long sought ways to mitigate the atrophy-inducing effects of unloading on skeletal muscle. An animal model used to study this effect involves suspending rats by their tails with only their front feet touching any surface of the cage. The muscle atrophy that results mimics that seen in humans after space flight. When GH or IGF-I has been supplied exogenously during tail suspension, the results indicated that the mass of the normally weight-bearing muscles was, in fact, conserved. Owing to the effects of these treatments on other tissues, however, the overall body weight of the rats had increased. It was as if the growth and development program from an earlier developmental stage had been reactivated. When compared with their body weight changes, however, the muscles had actually grown less—that is, the normalized muscle mass was less in treated than untreated animals—the end result being that the IGF-I-treated rats would ac-

tually be less well adapted to normal ambulatory activity than the rats that received no treatment at all.

In humans, the effects of attempts to augment muscle mass using IGF-I have been less dramatic. In studies designed to overcome the loss of muscle in the elderly, the overall effect of increasing circulating IGF-I levels experimentally has been negligible.²⁻⁴ In 1 study, the investigators managed to double the circulating IGF-I levels in elderly subjects but found no effect on the rate of protein synthesis in muscles and no augmentation of strength.⁴ In addition to this disappointing result, the supplementation of IGF-I in otherwise healthy—that is, GH-normal—people is associated with moderate-to-severe hypoglycemia (it is, after all, insulin-like),⁵ decreased GH secretion,^{6,7} a shift from lipid to carbohydrate oxidation for energy,⁷ and a general disruption of the insulin–glucagon system.^{5,7} The issue of augmenting IGF-I is rendered even more complex because the biologic activity of IGF-I in the body is substantially influenced by the family of IGF-binding proteins.⁸ For example, recent work on the effects of hypoxia on rat growth suggests that it is the effect of IGF-binding protein-3 that is more closely related to overall growth than is IGF-I itself.⁹

A more troubling aspect of IGF-I has recently emerged. In addition to a direct anabolic effect on skeletal muscle—for example, the production of more protein—IGF-I is also capable of stimulating the proliferation and differentiation of muscle stem cells (satellite cells). Results of animal studies suggest that this process is obligatory for muscle hypertrophy to proceed. Evidence that IGF-I is mitogenic should serve as a cautionary note to those who would use this agent to promote an anabolic state. Additional evidence suggests that IGF-I signaling may also participate in cellular transformation.¹⁰ Specifically, elevated IGF-I levels have been linked to prostate, colorectal, and lung cancers.¹¹

Given its potentially adverse effects, ranging from disruption of the insulin system to cancer, the exogenous augmentation of IGF-I is not an attractive or effective method of increasing muscle mass or function. Clearly, a prerequisite to the therapeutic use of these powerful growth factors is focused research on the mechanisms through which these mediators actually influence growth in the context of the whole organism.

References

- Adams GR. The role of IGF-I in the regulation of skeletal muscle adaptation. *Exerc Sport Sci Rev* 1998;26:31-60.
- Taaffe DR, Jin IH, Vu TH, et al. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression. *J Clin Endocrinol Metab* 1996;81:421-425.
- Taaffe DR, Pruitt L, Reim J, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. *J Clin Endocrinol Metab* 1994;79:1361-1366.
- Yarasheski KE, Zachwieja JJ, Campbell JA, et al. Effect of growth

- hormone and resistance exercise on muscle growth and strength in older men. *Am J Physiol* 1995;268:E268-E276.
- 5 Jenkins PJ. Growth hormone and exercise. *Clin Endocrinol* 1999;50:683-689.
- 6 Carroll PV, Umpleby M, Alexander EL, et al. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. *Clin Endocrinol* 1998;49:739-746.
- 7 Sherwin RS, Borg WP, Boulware SD. Metabolic effects of insulin-like growth factor-I in normal humans. *Horm Res* 1994;41(suppl 2):97-102.
- 8 Baxter, RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. *Am J Physiol* 2000;278:E967-E976.
- 9 Moromisato DY, Moromisato MY, Brasel JA, et al. Effect of growth hormone therapy in mitigating hypoxia-induced and food restriction-induced growth retardation in the newborn rat. *Crit Care Med* 1999;27:2234-2238.
- 10 Baserga, R. The IGF-I receptor in cancer research. *Exp Cell Res* 1999;253:1-6.
- 11 Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. *J Cell Physiol* 2000;183:1-9.